

References

1-Adinolfi LE, Utili R, Andreana A, et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001; 46: 1677-83.

2-Adinolfi LE, Utili R, Andreana A, Tripodi MF, Marracino M, Gambardella M, Giordano M, Ruggiero G. Institute of Medical Therapy, Faculty of Medicine, Second University of Naples, Italy Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C Dig Dis Sci. 2001 Aug;46(8):1677-83.

3-.Alberti A, Chemello L, Benvegna L. Natural history of hepatitis C. J Hepatol 1999;31:S17-S24.

4-Al-Khurri LE, Al-Khafaji KR, Al-Salihi SA, Alwaysi SAA, Al-Akayshi RJ. Serum HCV-RNA levels in patients with chronic hepatitis C: Correlation with histological features. Arab journal of Gastroenterology., 2009, 10 : 10-13.

5-Alter HJ, Seeff LB. (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. *Seminars in Liver Disease*; 20(1):17–35

6- Alter M.J. et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med*. 1999 ;341(8):556-62

7-Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. *N Engl J Med* 1989;321(22):1494

8-Adriulli A, Festa V, Leandro G, Rizzetto M, and AIGO Members. (2001) Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection. An AIGO study. *Dig Dis Sci*; 46:1409-15

9-Anonymous. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. *MMWR Recomm Rep* 2001;50(RR-11):1

10-Awad, T; Thorlund, K; Hauser, G; Stimac, D; Mabrouk, M; Gluud, C (2009). "Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials.". *Hepatology* (Baltimore, Md.) 51 (4): 1176–84. doi:20187106. PMID 20187106

11-Bastida G, Nos P, Aguas M, Beltrán B, Rubín A, Dasí F, Ponce J (2005). "Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease". *Aliment Pharmacology Ther* 22 (9): 775–82. Doi: 10.1111/j.1365-2036.2005.02636.x. PMID 16225485.

12-Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. *Am J Surg Pathol* 1995; 19:1409–1417.

13-Bedossa P, Poynard T, The French METAVR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. *Hepatology* 1996;24:289–293.

14-Bhupinder S. Anand, MD, Digestive Diseases Section (111D), VA Medical Center, 2002 Holcombe Blvd. Houston Texas 77030, USA. ana0@flash.net.

15-Boyer TD, Wright TL, Manns MP. Zakim and Boyer's Hepatology: a textbook of liver disease. 5th edition. Philadelphia: Saunders; 2006.

16- Cacoub P. *et al.* Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. *Medicine (Baltimore)*. 2000 ;79(1):47-56

17-Caruntu FA, Benea L (September 2009). "Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment". Journal of Gastrointestinal and Liver Diseases: JGLD 15 (3): 249–56. PMID 17013450.

18-Centers for Disease Control and Prevention. (2001). Recommendations for preventing transmission of infections among chronic hemodialysis patients. *MMWR*; 50 (RR-5): 28-29

19-Child CGI, Turcotte JG. Surgery and Portal Hypertension. In: Child CGI, ed. The Liver and portal hypertension. Philadelphia: WB Saunders; 1964:5

20-Choi Y, Putti T, Win K, Hu Y, Remy P, Bloom A.

Department of Pathology, Bronx-Lebanon Hospital Center, Bronx, New York, USA
Correlation of viral RNA, alanine aminotransferase, and histopathology in hepatitis C virus-associated hepatitis. *Mol Diagn.* 1999 Sep;4(3):251-4.

21-Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. *Gut* 1999;45(4):613.

22-. Comanor L, Anderson F, Ghany M, et al.

Transcription mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. *Am J Gastroenterol* 2001;96:2968-72.

23-Conjeevaram HS, Fried MW, Jeffers LJ, et al.(2006)

Peginterferon and ribavirin treatment in African American and Caucasian American patients with chronic hepatitis C genotype 1. *Gastroenterology.* 2006; 131:470–477.

24-De Moliner L, Pontisso P, de Salvo GL, Cavalletto L, Chemello L, Alberti A. Serum and liver HCVRNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. *Gut.*, 1998, 42 : 856-860.

25-Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology* 1994;19:1513–1520.

26-De Ledinghen V, Le Bail B, Rebouissoux L, Fournier C, Foucher J, Miette V, Castera L, Sandrin L, Merrouche W, Lavrand F, Lamireau T. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. *J Pediatr Gastroenterol Nutr* 2007,45(4):443-50

27-Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. *Hepatology* 1994;19:13-8.

28. ELENA RODRIGUEZ SUSANA de Lucas, Felix Manzarbeitia, Margarita Pardo, Carlos Arocena, Jaime Gosa Ivez, Horacio Oliva, and Vicente Carreno (Am J Pathol 1999,154:1877-1881

29-Fanning L, Kenny E, Sheehan M, et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 1999; 29 (3): 904–7.

30-Feldman: Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 7th ed., Copyright © 2002 Elsevier. 13031323.

31-Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65(6):2335

32-Forns X, Ampurdanes S, Llovet J et al.: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986–92.

33-Fox SI. The Digestive System. In: Human Physiology 4th ed. Dubuque IA): Wm. C. Brown Publishers; 1993.

34-Fouzia T Javed *, Bushra Ijaz, 1* Waqar Ahmad 1, Shah Jahan, 1, Saba Khaliq1 and Sajida Hassan1†
Department of Pathology Jinnah Hospital, Lahore; (1) Applied and Functional Genomics lab, Centre of Excellence in Molecular Biology University of the Punjab, LahorePakistanCorrelation of Serum HCV titer, ALP and Bilirubin Levels with Liver Fibrosis Stage2010

35-Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet*2000;355:887–891.

36-Francois M, Dubois F, Brand D, et al. Prevalence and significance of hepatitis C virus (HCV)viremia in HCV antibody-positive subjects from various populations. *J Clin Microbiol*1993;31(5):1189.

37-Fraquelli M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patientswith chronic liver disease. *Gut* 2007, 56:968.

38-Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. *Physiol Rev* 2008, 88(1):125-72

39-Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the Third AASLD SingleTopic Conference. *Hepatology* 2007, 45(1):242-9.

40-Fung J, Lai C-L, Hung I, et al. (2008). "Chronic Hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin". *J Infect Dis* 198 (6): 808–12. Doi: 10.1086/591252. PMID 18657036

41-Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature 461 (7262): 399–401. Doi:10.1038/nature08309. PMID 19684573

42-GhanyMG, KleinerDE, AlterHJ, DooE, Khokhar F, Park Y, Liang TJ, et al. Progression of fibrosis in early stages of chronic hepatitis C. *Hepatology* 2000;

43-Ghany, Marc & Hoofnagle, Jay H. (2005). Approach to the Patient with Liver Disease. In Dennis L. Kasper, Anthony S. Fauci, Dan L. Longo, Eugene Braunwald, Stephen L. Hauser, & J. Larry Jameson (Eds.), Harrison's Principles of Internal Medicine (16th Edition), pp. 1814–1815. New York: McGraw-Hill.

44-Gitto S, Micco L, Conti F, Andreone P, Bernardi M. Alcohol and viral hepatitis: A mini-review. *Dig Liver Dis* 2008.

45-Gordon, CS, Kodali, VP, Silverman, AL, et al. Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. *Am J Gastroenterol* 2008;89: 1458–1461.

46-Greenway CV, Lutt WW. Hepatic circulation. In: Schultz SG, Wood JD, Rauner BB, editors. *Handbook of Physiology. The Gastrointestinal System I. Part 2*, Chapter 41. Vol. 1. American Physiological Society; New York: Oxford University Press; 1989.

47-Gretch DR, Dela Rosa C, Carithers RL Jr, et al. Assessment of hepatitis C viremia using molecular amplification technologies: correlation and clinical implications. *Ann Intern Med* 1995; 123: 321-9.

48-. Gumber S.C, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. *Ann Intern Med.* 1995 ;123(8):615-20.

49-Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. *Medicine (Baltimore)* 2001;80(2):134.

50-Hoofnagle, J.H. (1997). Hepatitis C: the clinical spectrum of disease. *Hepatology* 26, 15S–20S.

51-Hraber P, Kuiken C, Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. *Hepatology* 2007;46(6):1713.

52-Iijima, A., E.Tankaka, M.Kobayashi, S.Yagi, M.Mizokami, and K.Kiyosawa. 2000. relation between histologic prognosis of chronic hepatitis C and amount of hepatitis C virus core protein in serum, *J Hepatol.* 22:696-699.

53-Imbert-Bismut F, Ratziu V, Piéroni C, Benhamou Y, Poinard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 2001; 357: 1069–75.

54-Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995;22:696–699.

55-Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G (2006). "A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection". *J. Viral Hepat.* 13 (11): 775–82. Doi: 10.1111/j.13652893.2006.00742.x. PMID 17052278

56-Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. *N Engl J Med.* 1999 ;340(16):1228-33.

57-Knodel IRG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1981;1:431–435.

58-Lagging LM, Garcia CE, Westin J, et al. Comparison of serum hepatitis C RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. *J Clin Microbiol* 2002;40(11):4224–9.

59-Lau, JYN, Davis, G, Kniffen, J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. *Lancet* 2006;341: 1501–1504.

60-Lefkowitz JH, Schiff ER, Davis GL, Perillo RP, Lindsay K, Bodenheimer HC, Balart LA, et al. Pathological diagnosis of chronic hepatitis C. A multicenter comparative study with chronic hepatitis B. *Gastroenterology* 1993;104:595-603.

61-Lim JR, Faught PR, Chalasani NP, Molleston JP (2006). "Severe liver injury after initiating therapy with atomoxetine in two children". J. Pediatr. 148 (6): 831–4. Doi: 10.1016/ j.jpeds. 2006.01.035. PMID 16769398.

62-Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. *Clin LiverDis* 2008;12(4):733.

63-Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. *J Hepatol.* 1999 ;31(Suppl 1):210-6.

64-Magrì, S, Craxì, A, Fabiano, C, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon- or corticosteroid treatment. *Hepatology* 1994;12: 273–279.

65-Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M (2007). "The way forward in HCV treatment—finding the right path". *Nat Rev Drug Discov* 6 (12): 991–1000. doi:10.1038/nrd2411

66-MartinezHernandezA, AmentaPS. Morphology, localization and origin of the hepatic extracellular matrix. : Zern MA, Reid L M eds. *Extracellular Matrix, Chemistry, Biology and Pathobiology With Emphasis on the Liver*. New-York: Dekker, 1993: 201–254.

67-Melissa Palmer.(2004), MD is the author of "Dr. Melissa Palmer's Guide of Hepatitis and Liver Disease". (Published 2004. Penguin Putnam).

68-Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. *Hepatology* 1992;16(5):1109.

69-Morales TJ, Samplier RE, Bhattacharyya A. Liver histology in individuals with positive markers for HCV and normal or minimally elevated aminotransferases. *Am J Gastroenterol* 1994; 47: 1674-8.

70-National Institutes of Health consensus development conference statement. Management of hepatitis C: 1012 June 2002. <http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm>. Last accessed 22 December 2009.

71-Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. *N Engl J Med* 1994;330(11):744.

72-Okuda M, Li K, Beard MR, Showalter LA, Scolle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis c virus core protein. *Gastroenterology* 2002;122:366-375.

73-Olariu M, Olariu C, Olteanu D. National Institute of Infectious Diseases "Prof. Dr. Matei Balș" Bucharest, Romania. ol_mihai@yahoo.com *J Gastrointest Liver Dis.* 2010 Dec;19(4):381-5.

74-ParadisV, MathurinP, LaurentA, Charlote F, VidaudM, PoynardT, HoangC,*etal.* Histologic features predictive of liver fibrosis in chronic hepatitis C infection. *J Clin Pathol* 1996; 49:1–7

.

75-Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. *N Engl J Med* 1991;325(7):454.

76-PohlA, Behling C, Oliver D, Kilani M, Monson P, Hassanein T: Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. *Am J Gastroenterol* 2001; 96: 3142–6.

77-Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. *Curr Opin Hematol* 2003;10(6):412.

78-Poynard T, Bedossa P, Opolon P. Natural history of fibrosis progression in patients with hepatitis C. *Lancet* 1997;349:825–832.

79-Poynard T, Ratziu V, Charlotte F, Goodman Z, Mchutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. *J Hepatol* 2001; 34:730–739.

80-Proceedings of the June 10–12 “Management of Hepatitis C: 2002. National Institutes of Health Consensus Development Conference Update.” *Hepatology*. 2002;36(5, part 2).

81-Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. *Hepatology*. 1997;26:1393–1398.

82-Rockey DC. Hepatic Fibrosis, Stellate Cells, and Portal Hypertension. *Clinics in Liver Disease* 2006 ; 10(3):459-479.

83- Rodriguez-Inigo E, Bartolome J, Lucas de S, et al. Histological damage in chronic hepatitis C is not related to the extent of infection in the liver. *Am J Pathol* 1999; 154: 1877-81.

84-Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. *Kidney Int* 1994;45(1):238.

85-Ryder S, Beckingham I (2001). "ABC of diseases of liver, pancreas, and biliary system: Acute hepatitis". BMJ 322 (7279): 151–153. doi:10.1136/bmj.322.7279.151. PMID 11159575.

86-S. N. Hashmi, N. Saleem, A. Mubarik, A. H. Qureshi, M. Ahmad, S. Afzal (Department of Pathology, Army Medical College) M. Siddiq (Department of Pathology, Military Hospital*) A. B. Hussain (Department of Pathology, Armed Forces Institute of Pathology**, Rawalpindi.) 2003.

87-Saleem N, Mubarik A, Qureshi AH, et al. Is there a correlation between degree of viremia and liver histology in chronic hepatitis C? *J Pak Med Assoc* 2004;54(9):476–9.

88-Sandrin L, Catheline S, Tanter M, Hennequin X, Fink M. Time-resolved pulsed elastography with ultrafast ultrasonic imaging. *Ultrason Imaging* 1999, 21(4):259-72

89-Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M, Schuppan D. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. *Gastroenterology* 2005;129:246-258.

90-Sebastiani G, Alberti A. Noninvasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. *World Gastroenterol* 2006;12(23): 3682 -3694.

91- Seeff L.B. *et al.* Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. *Hepatology*. 2001 ;33(2):455-63

92-Sharara, AI, Hunt, CM, Hamilton, JD. Hepatitis C. *Ann Intern Med* 1996;125: 658–668.

93-Shiffman ML, Suter F, Bacon BR, et al. (2007).

"Peginterferon Alfa-2a and Ribavirin for 16 or 24 weeks in HCV genotype 2 or 3". *N Engl J Med* 357 (2): 124–34. doi:10.1056/NEJMoa066403. PMID 17625124.

<http://content.nejm.org/cgi/content/short/357/2/124?query=TOC>

94-Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Bräu N, et al. (2007)
Care of patients coinfecting with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel AIDS 2007; 21(9): 1073-89.

95-Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004;2(6):469.

96-Strader DB, Wright T, Thomas DL, Seeff LB. (2004)
Diagnosis, management, and treatment of hepatitis C. *Hepatology*. 2004; 39:1147–1171.

97-Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004;2(6):469.

98-Sutton AJ, Hope VD, Mathei C, et al. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. *J Viral Hepat* 2008;15(11):809.

99-The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology* 1994;20:15–20

100-Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med* 1993;328:1797–1801.

101-Vandelli C, Renzo F, Romanò L, et al. (2004). "Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study". Am J Gastroenterol. 99 (5): 855–9. doi:10.1111/j.1572-0241.2004.04150.x. PMID 15128350.

102-Villano S.A. *et al.* Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. *Hepatology*. 1999 ;29(3):908-14

103-WaiC, Greenson JK, Fontana RJ et al.: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; 38: 518–26.

104-Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis--United States, 2006. *MMWR Surveill Summ* 2008;57(2):1.

105-WHO. Hepatitis C: global update. *Wkly Epidemiol Rec* 1997;72:341–344.

106-WHO. Hepatitis C – global update. *Wkly Epidemiol Rec* 1999;74:425–427

107-Zechini B et al found a significant correlation between HCV RNA and aminotransferase levels and observed a significant correlation between HCV RNA levels and histological activity index

108-Zeuzem S, Lee J-H, Franke A, et al.. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. *Hepatology* 27: 1149-56, 1998

109-Zeuzem S, Franke A, Lee JH, et al. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. *Hepatology*. 2000;24:1003–1009.